KATIE ROBINSON: Open Payments
NPI 1598400053 · LYNCHBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,191 in 45 payments from 12 companies in 2025. Trend: 2023 $31 · 2024 $86 · 2025 $1,191
Food & beverage: $894Education: $297
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $271 |
| Regeneron Healthcare Solutions, Inc. | 7 | $238 |
| SANOFI-AVENTIS U.S. LLC | 2 | $199 |
| GENZYME CORPORATION | 6 | $159 |
| Novartis Pharmaceuticals Corporation | 6 | $122 |
| Genentech USA, Inc. | 3 | $70 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Verona Pharma, Inc. | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: DUPIXENT, AIRSUPRA, Xolair, BREZTRI, Rhapsido, FASENRA, NEFFY, TAKHZYRO.
Industry payments across VA — which companies pay providers there.
